Grufity logoGrufity logo

GILD

89.03USD+1.13(+1.29%)Market Closed

Gilead Sciences Inc

Market Summary

USD89.03+1.13Market Closed
1.29%

GILD Alerts

GILD Stock Price

RSI Chart

Valuation

Market Cap

99.4B

Price/Earnings

24.02

Price/Sales

3.61

Price/Cashflow

9.84

MarketCap/EBT

17.91

Price/Sales

Profitability

EBT Margin

20.16%

Return on Equity

20.44%

Return on Assets

6.58%

Fundamentals

Revenue

Revenue (TTM)

27.1B

Revenue Y/Y

-5.11%

Revenue Q/Q

12.49%

Earnings

Earnings (TTM)

3.3B

Earnings Y/Y

-30.98%

Earnings Q/Q

56.38%

Price Action

52 Week Range

55.2789.07
(Low)(High)

Last 7 days

3.2%

Last 30 days

14.3%

Last 90 days

41.1%

Trailing 12 Months

33.9%

Financial Health

Current Ratio

1.43

Debt/Equity

1.3

Debt/Cashflow

0.39

Investor Care

Dividend Yield

3.63%

Dividend/Share (TTM)

2.9

Buy Backs (1Y)

0.01%

Diluted EPS (TTM)

2.65

Peers (Alternatives to Gilead Sciences)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
146.5B
26.3B
6.86% 46.41%
22.27
5.55
2.18% 21.86%
99.4B
27.1B
14.32% 33.87%
24.02
3.61
-1.26% -54.91%
59.1B
23.0B
22.70% -39.52%
4.2
2.57
227.55% 302.16%
41.3B
10.4B
7.38% 30.80%
14.4
3.98
-6.64% 85.32%
11.1B
1.4B
3.89% 57.25%
905.99
8.52
29.86% -86.92%
MID-CAP
3.7B
112.4M
6.18% -26.69%
-12.87
32.5
-41.50% -607.58%
3.4B
-
7.39% -35.47%
-14.65
59.51
215916.67% 21.41%
2.1B
68.3M
4.34% -60.25%
-8.33
30.98
42.18% -19.70%
2.0B
432.8M
45.87% -20.63%
29.99
4.9
1042.97% 128.67%
SMALL-CAP
1.8B
1.8B
-19.41% -89.80%
-1.22
1.39
53.41% -22.97%
1.6B
69.7M
-4.82% -76.34%
-3.15
20.84
745.14% -7.72%
891.0M
3.2M
5.78% -29.88%
-6.7
275.59
11.14% -46.59%
692.0M
114.2M
-14.32% -56.80%
-4.02
6.06
-17.11% -27.41%
458.1M
-
-17.48% -90.68%
-13.56
44.06
522.71% -129.91%
218.9M
-
-15.58% -80.57%
-2.36
609.63
-71.03% -64.56%

Financials for Gilead Sciences

Income Statement (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Revenue-1.4%27,13627,51527,47227,30527,482
  S&GA Expenses0.4%5,3035,2805,2745,2465,326
Earnings Before Taxes-18.1%4,5425,5485,8628,2789,333
Net Income-19.4%3,3344,1374,5156,2257,394
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Assets-0.5%62,55762,87063,08067,95267,098
  Current Assets2.9%13,55413,17512,62914,77213,991
    Cash Equivalents-0.8%4,6994,7394,2965,3384,362
  Inventory-2.1%1,4631,4941,4821,6181,676
  Net PPE0.9%5,3495,2995,2535,1215,037
  Goodwill0%8,3148,3148,3148,3328,332
  Current Liabilities13.0%10,4239,2208,55811,61010,245
  Long Term Debt-3.8%25,22326,21626,20826,69527,686
    LT Debt, Current122.3%2,2701,0211,0251,5162,511
    LT Debt, Non Current-8.9%22,95325,19525,18325,17925,175
Shareholder's Equity4.2%21,08120,23619,92721,06921,470
  Retained Earnings4.2%15,75615,11714,98616,32416,903
  Additional Paid-In Capital3.9%5,2265,0314,8674,6614,492
Accumulated Depreciation-1,893----
Shares Outstanding0%1,2541,2541,2551,2541,255
Minority Interest-14.3%-24.00-21.00-12.00-5.001
* denotes actual numbers (not divided by Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Cashflow From Operations-3.9%9,71010,10010,61411,38410,095
  Share Based Compensation-0.5%622625626635637
Cashflow From Investing-25.3%-2,369.00-1,890.00-2,159.00-3,131.00-11,830.00
Cashflow From Financing17.0%-6,857.00-8,266.00-8,194.00-8,877.00-6,804.00
  Dividend Payments0.8%3,6883,6593,6333,6053,569
  Buy Backs6.7%713668633546541

Risks

What is the probability of a big loss on GILD?

50.8%


Probability that Gilead Sciences stock will be more than 20% underwater in next one year

0%


Probability that Gilead Sciences stock will be more than 30% underwater in next one year.

0%


Probability that Gilead Sciences stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does GILD drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Gilead Sciences was unfortunately bought at previous high price.

Returns

Cumulative Returns on GILD

11.9%


10-Year Cumulative Returns

1.3%


7-Year Cumulative Returns

7.5%


5-Year Cumulative Returns

15.2%


3-Year Cumulative Returns

What are the long-term rolling returns for GILD?

FIve years rolling returns for Gilead Sciences.

Which funds bought or sold GILD recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-29
Bridgefront Capital, LLC
SOLD OFF
-100
-220,000
-
-%
2022-11-23
Invst, LLC
ADDED
1.92
32,000
821,000
0.14%
2022-11-23
Gould Capital, LLC
NEW
-
8,000
8,000
0.01%
2022-11-23
Toroso Investments, LLC
ADDED
4.19
173,000
4,508,000
0.19%
2022-11-23
Eagle Bay Advisors LLC
ADDED
28.66
19,492
87,000
0.05%
2022-11-22
IHT Wealth Management, LLC
ADDED
26.97
120,000
571,000
0.04%
2022-11-22
CONTINENTAL INVESTORS SERVICES, INC.
NEW
-
214,000
214,000
0.01%
2022-11-22
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
NEW
-
7,355,000
7,355,000
0.09%
2022-11-22
B. Riley Wealth Advisors, Inc.
ADDED
32.81
367,000
1,492,000
0.04%
2022-11-22
CVA Family Office, LLC
ADDED
54.79
29,000
83,000
0.02%

1–10 of 47

Latest Funds Activity

Are funds buying GILD calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own GILD

Gilead Sciences News

MarketWatch

Regeneron Pharmaceuticals Inc. stock rises Friday, outperforms market.11 hours ago

Yahoo Finance

GILD Fair Value

Recent SEC filings of Gilead Sciences

View All Filings
Date Filed Form Type Document
Nov 14, 2022
4
Insider Trading
Nov 14, 2022
4
Insider Trading
Nov 10, 2022
4
Insider Trading
Nov 02, 2022
10-Q
Quarterly Report
Nov 02, 2022
4
Insider Trading
Oct 27, 2022
8-K
Current Report
Sep 12, 2022
4
Insider Trading
Sep 12, 2022
4
Insider Trading
Sep 12, 2022
4
Insider Trading
Sep 12, 2022
4
Insider Trading

Latest Insider Trading transactions for GILD

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-11-10
Dickinson Andrew D
SOLD FOR TAXES
-70,292.6
82.6
-851
Chief Financial Officer
2022-11-10
Dickinson Andrew D
ACQUIRED
-
-
1,912
Chief Financial Officer
2022-11-10
Parsey Merdad
SOLD FOR TAXES
-187,337
82.6
-2,268
Chief Medical Officer
2022-11-10
Parsey Merdad
ACQUIRED
-
-
5,099
Chief Medical Officer
2022-11-09
Wilfong Diane E.
SOLD
-535,736
83.5
-6,416
SVP, Controller & CAO
2022-11-09
Wilfong Diane E.
ACQUIRED
410,047
63.91
6,416
SVP, Controller & CAO
2022-11-01
Wilfong Diane E.
SOLD
-1,288,210
79.25
-16,255
SVP, Controller & CAO
2022-11-01
Wilfong Diane E.
ACQUIRED
1,181,740
72.7
16,255
SVP, Controller & CAO
2022-09-10
Parsey Merdad
SOLD (Taxes)
-31,399.7
65.28
-481
Chief Medical Officer
2022-09-10
Mercier Johanna
ACQUIRED
-
-
990
Chief Commercial Officer

1–10 of 50

Daniel P. O'Day
14400
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.

GILD Income Statement

2022-09-30
CONDENSED CONSOLIDATED STATEMENTS OF INCOME - USD ($)
shares in Millions, $ in Millions
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Revenues:    
Total revenues$ 7,042$ 7,421$ 19,892$ 20,061
Costs and expenses:    
Cost of goods sold1,3951,2234,2613,974
Research and development expenses1,1491,1013,4293,243
Acquired in-process research and development expenses44865786270
In-process research and development impairment002,7000
Selling, general and administrative expenses1,2131,1903,6533,596
Total costs and expenses4,2053,57914,82911,083
Income from operations2,8373,8425,0638,978
Interest expense(229)(250)(709)(763)
Other income (expense), net(176)(154)(571)(696)
Income before income taxes2,4323,4383,7837,519
Income tax expense(646)(852)(850)(1,694)
Net income1,7862,5862,9335,825
Net loss attributable to noncontrolling interest361918
Net income attributable to Gilead$ 1,789$ 2,592$ 2,952$ 5,843
Net income per share attributable to Gilead common stockholders - basic (in dollars per share)$ 1.43$ 2.06$ 2.35$ 4.65
Shares used in per share calculation - basic (in shares)1,2551,2561,2551,256
Net income per share attributable to Gilead common stockholders - diluted (in dollars per share)$ 1.42$ 2.05$ 2.34$ 4.63
Shares used in per share calculation - diluted (in shares)1,2611,2621,2611,262
Product sales    
Revenues:    
Total revenues$ 6,978$ 7,356$ 19,650$ 19,848
Royalty, contract and other revenues    
Revenues:    
Total revenues$ 64$ 65$ 242$ 213

GILD Balance Sheet

2022-09-30
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Millions
Sep. 30, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 4,699$ 5,338
Short-term marketable debt securities9611,182
Accounts receivable, net4,3544,493
Inventories1,4631,618
Prepaid and other current assets2,0772,141
Total current assets13,55414,772
Property, plant and equipment, net5,3495,121
Long-term marketable debt securities1,2821,309
Intangible assets, net29,44033,455
Goodwill8,3148,332
Other long-term assets4,6184,963
Total assets62,55767,952
Current liabilities:  
Accounts payable614705
Accrued government and other rebates3,6743,244
Accrued and other current liabilities3,8656,145
Current portion of long-term debt and other obligations, net2,2701,516
Total current liabilities10,42311,610
Long-term debt, net22,95325,179
Long-term income taxes payable3,9824,767
Deferred tax liability3,0364,356
Other long-term obligations1,106976
Commitments and contingencies (Note 10)
Stockholders’ equity:  
Preferred stock, par value $0.001 per share; 5 shares authorized; none outstanding00
Common stock, par value $0.001 per share; 5,600 shares authorized; 1,254 shares issued and outstanding11
Additional paid-in capital5,2264,661
Accumulated other comprehensive income9883
Retained earnings15,75616,324
Total Gilead stockholders’ equity21,08121,069
Noncontrolling interest(24)(5)
Total stockholders’ equity21,05721,064
Total liabilities and stockholders’ equity$ 62,557$ 67,952